Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central nervous system, conolidine modulates alternate molecular targets. A Science Innovations study located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://bertieh025gbu2.vblogetin.com/profile